Movatterモバイル変換


[0]ホーム

URL:


Journal Logo

Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.

Export to

MYELOID BIOLOGY: Edited by David C. Dale

An update on the diagnosis and treatment of chronic idiopathic neutropenia

Dale, David C.a; Bolyard, Audrey A.b

Author Information

aDepartment of Medicine

bDepartment of Medicine, Severe Chronic Neutropenia International Registry, University of Washington, Seattle, Washington, USA

Correspondence to David C. Dale, MD, Department of Medicine, University of Washington, Box 356422, 1959 NE Pacific St., Rm AA522, Seattle, WA 98195, USA. Tel: +1 206 543 7215; fax: +1 206 685 4458; e-mail:[email protected]

Current Opinion in Hematology24(1):p 46-53, January 2017. |DOI:10.1097/MOH.0000000000000305

Abstract

Purpose of review 

Neutropenia lasting for at least for 3 months and not attributable to drugs or a specific genetic, infectious, inflammatory, autoimmune or malignant cause is called chronic idiopathic neutropenia (CIN). CIN and autoimmune neutropenia (AIN) are very similar and overlapping conditions. The clinical consequences depend upon the severity of neutropenia, but it is not considered a premalignant condition.

Recent findings 

Long-term observational studies in children indicate that the disease often lasts for 3–5 years in children, then spontaneously remits, but it rarely remits in adult cases. The value of antineutrophil antibody testing in both children and adults is uncertain. Most recent data suggest that CIN and AIN are immune-mediated diseases, but there are no new clinical or genetic tests to aid in diagnosis. Treatment with granulocyte colony stimulating factor (G-CSF) is effective to increase blood neutrophils in almost all cases; this treatment is reserved, however, for patients with both neutropenia and evidence of recurrent fevers, inflammatory symptoms and infections. There is little or no evidence to indicate that G-CSF treatment predisposes to myeloid malignancies in this population.

Summary 

It is important to recognize CIN and AIN, the most common causes of chronic neutropenia in both children and adults. If the neutropenia is not severe, that is more than 0.5 × 109/l, most patients can be observed and not treated prophylactically with antibiotics or a growth factor. When neutropenia is severe, treatment with G-CSF is often beneficial.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Log InAccess through Ovid

Source

Current Opinion in Hematology24(1):46-53, January 2017.
Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.


[8]ページ先頭

©2009-2025 Movatter.jp